O. Abu-Hammad, Diana Arabiat, Nebras Althagafi, Rawah Eshky, Abdalla Abu-Hammad, Abdul-Raheem Jaber, Abdel Rahman Jaber, N. Dar-Odeh
{"title":"2022 年猴痘爆发中成年男性患者的性传播疾病和艾滋病毒合并感染:系统回顾和荟萃分析","authors":"O. Abu-Hammad, Diana Arabiat, Nebras Althagafi, Rawah Eshky, Abdalla Abu-Hammad, Abdul-Raheem Jaber, Abdel Rahman Jaber, N. Dar-Odeh","doi":"10.4081/dr.2024.9860","DOIUrl":null,"url":null,"abstract":"Aim. This meta-analysis estimates the prevalence of sexually transmitted diseases (STIs) and HIV infection among male patients diagnosed with Monkeypox during the 2022 outbreak. The study also explores contextual factors associated with higher risk of monkeypox infection. Methods. A systematic review of literature was initially conducted through PubMed/ Medline, Scopus, and Google Scholar to retrieve observational studies describing demographics and medical characteristics of Monkeypox patients affected in the 2022 outbreak. The System for the Unified Management, Assessment, and Review of Information -Joanna Briggs Institute (SUMARI JBI) guidelines was used to conduct the meta-analysis of this review. All data relevant to prevalence of HIV and STIs in male patients diagnosed with Monkeypox were extracted and exported into the JBI SUMARI. To assess point prevalence of HIV and STIs, we used the Freeman-Tukey-type arcsine square root transformation to stabilize the variances of the raw proportions. All estimates were weighted and pooled by the inverse variance using a fixed-effects model. We then used a random model to account for sampling variation and reported heterogeneity in effect size noted across studies in the fixed-effect model. The I2 test statistic and P values were used to measure the heterogeneity between studies. Values of I2 test statistic results were interpreted as follows: low (25%), moderate (50%) and high (75%). Results. Six studies from Spain and the UK met the inclusion criteria. These studies described a total of 541 male patients with monkeypox, 214 of them were positive for HIV and 255 had other STIs. Overall estimated prevalence of HIV and STIs was 40% (95% CI = 0.31%, 0.50%; ᵡ2 = 15) and 43% (95% CI = 25%, 61%; ᵡ2 = 118), respectively. Outcomes indicated moderate to high heterogeneity in the overall analyses. Conclusions. Approximately four in ten male patients affected in the 2022 Monkeypox outbreak had HIV and/or other STIs. Necessary public health measures should target male and female patients who are at risk of Monkeypox infection to prevent the transmission of serious infections such as HIV and other STIs.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sexually transmitted diseases and HIV co-infection among adult male patients in the 2022 monkeypox outbreak: a systematic review and meta-analysis\",\"authors\":\"O. Abu-Hammad, Diana Arabiat, Nebras Althagafi, Rawah Eshky, Abdalla Abu-Hammad, Abdul-Raheem Jaber, Abdel Rahman Jaber, N. Dar-Odeh\",\"doi\":\"10.4081/dr.2024.9860\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim. This meta-analysis estimates the prevalence of sexually transmitted diseases (STIs) and HIV infection among male patients diagnosed with Monkeypox during the 2022 outbreak. The study also explores contextual factors associated with higher risk of monkeypox infection. Methods. A systematic review of literature was initially conducted through PubMed/ Medline, Scopus, and Google Scholar to retrieve observational studies describing demographics and medical characteristics of Monkeypox patients affected in the 2022 outbreak. The System for the Unified Management, Assessment, and Review of Information -Joanna Briggs Institute (SUMARI JBI) guidelines was used to conduct the meta-analysis of this review. All data relevant to prevalence of HIV and STIs in male patients diagnosed with Monkeypox were extracted and exported into the JBI SUMARI. To assess point prevalence of HIV and STIs, we used the Freeman-Tukey-type arcsine square root transformation to stabilize the variances of the raw proportions. All estimates were weighted and pooled by the inverse variance using a fixed-effects model. We then used a random model to account for sampling variation and reported heterogeneity in effect size noted across studies in the fixed-effect model. The I2 test statistic and P values were used to measure the heterogeneity between studies. Values of I2 test statistic results were interpreted as follows: low (25%), moderate (50%) and high (75%). Results. Six studies from Spain and the UK met the inclusion criteria. These studies described a total of 541 male patients with monkeypox, 214 of them were positive for HIV and 255 had other STIs. Overall estimated prevalence of HIV and STIs was 40% (95% CI = 0.31%, 0.50%; ᵡ2 = 15) and 43% (95% CI = 25%, 61%; ᵡ2 = 118), respectively. Outcomes indicated moderate to high heterogeneity in the overall analyses. Conclusions. Approximately four in ten male patients affected in the 2022 Monkeypox outbreak had HIV and/or other STIs. Necessary public health measures should target male and female patients who are at risk of Monkeypox infection to prevent the transmission of serious infections such as HIV and other STIs.\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-02-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2024.9860\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2024.9860","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的这项荟萃分析估计了2022年猴痘爆发期间被诊断为猴痘的男性患者中性传播疾病(STI)和艾滋病病毒(HIV)的感染率。研究还探讨了与猴痘感染风险较高相关的背景因素。研究方法首先通过PubMed/ Medline、Scopus和Google Scholar对文献进行系统回顾,检索描述2022年疫情中猴痘患者的人口统计学和医学特征的观察性研究。本综述采用乔安娜-布里格斯研究所信息统一管理、评估和审查系统(SUMARI JBI)指南进行荟萃分析。所有与被诊断为猴痘的男性患者中 HIV 和 STI 感染率相关的数据都被提取并导出到 JBI SUMARI 中。为了评估 HIV 和 STI 的点流行率,我们使用了 Freeman-Tukey-type arcsine 平方根变换来稳定原始比例的方差。使用固定效应模型对所有估计值进行加权并按反方差进行汇总。然后,我们使用随机模型来解释抽样差异,并报告了固定效应模型中各研究效应大小的异质性。我们使用 I2 检验统计量和 P 值来衡量研究之间的异质性。I2 检验统计结果的数值解释如下:低(25%)、中(50%)和高(75%)。结果。来自西班牙和英国的六项研究符合纳入标准。这些研究共描述了541名猴痘男性患者,其中214人HIV检测呈阳性,255人患有其他性传播疾病。HIV和性传播感染的总体估计发病率分别为40%(95% CI = 0.31%,0.50%;ᵡ2 = 15)和43%(95% CI = 25%,61%;ᵡ2 = 118)。总体分析结果显示存在中度到高度异质性。结论在 2022 年猴痘疫情中,每 10 名男性患者中约有 4 人感染了 HIV 和/或其他性传播疾病。必要的公共卫生措施应针对有感染猴痘风险的男性和女性患者,以防止艾滋病毒和其他性传播疾病等严重感染的传播。
Sexually transmitted diseases and HIV co-infection among adult male patients in the 2022 monkeypox outbreak: a systematic review and meta-analysis
Aim. This meta-analysis estimates the prevalence of sexually transmitted diseases (STIs) and HIV infection among male patients diagnosed with Monkeypox during the 2022 outbreak. The study also explores contextual factors associated with higher risk of monkeypox infection. Methods. A systematic review of literature was initially conducted through PubMed/ Medline, Scopus, and Google Scholar to retrieve observational studies describing demographics and medical characteristics of Monkeypox patients affected in the 2022 outbreak. The System for the Unified Management, Assessment, and Review of Information -Joanna Briggs Institute (SUMARI JBI) guidelines was used to conduct the meta-analysis of this review. All data relevant to prevalence of HIV and STIs in male patients diagnosed with Monkeypox were extracted and exported into the JBI SUMARI. To assess point prevalence of HIV and STIs, we used the Freeman-Tukey-type arcsine square root transformation to stabilize the variances of the raw proportions. All estimates were weighted and pooled by the inverse variance using a fixed-effects model. We then used a random model to account for sampling variation and reported heterogeneity in effect size noted across studies in the fixed-effect model. The I2 test statistic and P values were used to measure the heterogeneity between studies. Values of I2 test statistic results were interpreted as follows: low (25%), moderate (50%) and high (75%). Results. Six studies from Spain and the UK met the inclusion criteria. These studies described a total of 541 male patients with monkeypox, 214 of them were positive for HIV and 255 had other STIs. Overall estimated prevalence of HIV and STIs was 40% (95% CI = 0.31%, 0.50%; ᵡ2 = 15) and 43% (95% CI = 25%, 61%; ᵡ2 = 118), respectively. Outcomes indicated moderate to high heterogeneity in the overall analyses. Conclusions. Approximately four in ten male patients affected in the 2022 Monkeypox outbreak had HIV and/or other STIs. Necessary public health measures should target male and female patients who are at risk of Monkeypox infection to prevent the transmission of serious infections such as HIV and other STIs.